GE HealthCare expands invasive cardiology solutions portfolio with AltiX AI.i for elevated experience in catheterization lab and electrophysiology procedures
GE HealthCare (GEHC) has launched the AltiX AI.i edition of Mac-Lab, CardioLab, and ComboLab, enhancing cardiac catheterization and electrophysiology procedures. This advancement comes as cardiovascular disease affects over 500 million people globally, having nearly doubled in three decades.
The new solutions offer:
- Mac-Lab: Features diastolic pressure ratio algorithm and Cath Lab Command Center access
- CardioLab: Includes Prucka 3 digital amplifier for improved signal quality and Volta Interface for AI-powered atrial fibrillation assessment
- ComboLab: Integrates EP and hemodynamic recording in a single system
AltiX AI.i is currently available for order in the United States, with global markets launch planned later this year. The company will showcase these solutions at EHRA 2025 in Vienna and HRS 2025 in San Diego.
GE HealthCare (GEHC) ha lanciato l'edizione AltiX AI.i di Mac-Lab, CardioLab e ComboLab, migliorando le procedure di cateterismo cardiaco e di elettrofisiologia. Questo progresso arriva in un momento in cui le malattie cardiovascolari colpiscono oltre 500 milioni di persone in tutto il mondo, quasi raddoppiate in tre decenni.
Le nuove soluzioni offrono:
- Mac-Lab: Include l'algoritmo del rapporto di pressione diastolica e l'accesso al Centro di Comando della Sala Cateteri
- CardioLab: Comprende l'amplificatore digitale Prucka 3 per una qualità del segnale migliorata e l'interfaccia Volta per la valutazione dell' fibrillazione atriale potenziata dall'IA
- ComboLab: Integra la registrazione EP e emodinamica in un unico sistema
AltiX AI.i è attualmente disponibile per ordinazione negli Stati Uniti, con un lancio nei mercati globali previsto per la fine di quest'anno. L'azienda presenterà queste soluzioni all'EHRA 2025 a Vienna e all'HRS 2025 a San Diego.
GE HealthCare (GEHC) ha lanzado la edición AltiX AI.i de Mac-Lab, CardioLab y ComboLab, mejorando los procedimientos de cateterismo cardíaco y electrofisiología. Este avance se produce mientras que las enfermedades cardiovasculares afectan a más de 500 millones de personas en todo el mundo, casi duplicándose en tres décadas.
Las nuevas soluciones ofrecen:
- Mac-Lab: Presenta el algoritmo de relación de presión diastólica y acceso al Centro de Comando de Cateterismo
- CardioLab: Incluye el amplificador digital Prucka 3 para una mejor calidad de señal y la interfaz Volta para la evaluación de la fibrilación auricular impulsada por IA
- ComboLab: Integra el registro EP y hemodinámico en un solo sistema
AltiX AI.i está actualmente disponible para pedidos en los Estados Unidos, con un lanzamiento en mercados globales previsto para más adelante este año. La compañía mostrará estas soluciones en EHRA 2025 en Viena y HRS 2025 en San Diego.
GE 헬스케어 (GEHC)는 심장 카테터 시술 및 전기생리학 절차를 개선하기 위해 AltiX AI.i 에디션의 Mac-Lab, CardioLab 및 ComboLab을 출시했습니다. 이 발전은 심혈관 질환이 전 세계적으로 5억 명 이상의 사람들에게 영향을 미치고 있으며, 지난 30년 동안 거의 두 배로 증가한 상황에서 이루어졌습니다.
새로운 솔루션은 다음과 같은 기능을 제공합니다:
- Mac-Lab: 이완기 압력 비율 알고리즘 및 카테터 실험실 명령 센터 접근 기능 포함
- CardioLab: 향상된 신호 품질을 위한 Prucka 3 디지털 증폭기 및 인공지능 기반의 심방세동 평가를 위한 Volta 인터페이스 포함
- ComboLab: 단일 시스템에서 EP 및 혈역학적 기록 통합
AltiX AI.i는 현재 미국에서 주문할 수 있으며, 글로벌 시장 출시가 올해 말에 계획되어 있습니다. 이 회사는 비엔나에서 열리는 EHRA 2025와 샌디에고에서 열리는 HRS 2025에서 이러한 솔루션을 선보일 예정입니다.
GE HealthCare (GEHC) a lancé l'édition AltiX AI.i de Mac-Lab, CardioLab et ComboLab, améliorant les procédures de cathétérisme cardiaque et d'électrophysiologie. Cette avancée intervient alors que les maladies cardiovasculaires touchent plus de 500 millions de personnes dans le monde, ayant presque doublé en trois décennies.
Les nouvelles solutions offrent :
- Mac-Lab : Comprend un algorithme de rapport de pression diastolique et un accès au Centre de Commande de la Salle de Cathéter
- CardioLab : Inclut l'amplificateur numérique Prucka 3 pour une qualité de signal améliorée et l'interface Volta pour l'évaluation de la fibrillation auriculaire alimentée par l'IA
- ComboLab : Intègre l'enregistrement EP et hémodynamique dans un seul système
AltiX AI.i est actuellement disponible à la commande aux États-Unis, avec un lancement sur les marchés mondiaux prévu plus tard cette année. L'entreprise présentera ces solutions lors de l'EHRA 2025 à Vienne et de l'HRS 2025 à San Diego.
GE HealthCare (GEHC) hat die AltiX AI.i Edition von Mac-Lab, CardioLab und ComboLab auf den Markt gebracht, um die Verfahren der Herzkatheterisierung und Elektrophysiologie zu verbessern. Dieser Fortschritt erfolgt zu einem Zeitpunkt, an dem Herz-Kreislauf-Erkrankungen weltweit über 500 Millionen Menschen betreffen und sich in den letzten drei Jahrzehnten fast verdoppelt haben.
Die neuen Lösungen bieten:
- Mac-Lab: Verfügt über einen Algorithmus für das diastolische Druckverhältnis und Zugriff auf das Katheterlabor-Kommandocenter
- CardioLab: Enthält den digitalen Verstärker Prucka 3 für verbesserte Signalqualität und die Volta-Schnittstelle zur KI-gestützten Bewertung von Vorhofflimmern
- ComboLab: Integriert EP- und hämodynamische Aufzeichnung in einem einzigen System
AltiX AI.i ist derzeit in den Vereinigten Staaten erhältlich, mit einer globalen Markteinführung, die später in diesem Jahr geplant ist. Das Unternehmen wird diese Lösungen auf der EHRA 2025 in Wien und der HRS 2025 in San Diego präsentieren.
- Launch of new AI-enhanced cardiac procedure solutions expanding product portfolio
- Product addresses growing market with CVD affecting 500M+ people globally
- Received 2024 Company of the Year award in Global Next-Generation EP Labs Industry
- FDA 510(k) clearance already obtained for US market
- CE mark still pending for European market access
- initial availability to US market only
Insights
GE HealthCare's launch of AltiX AI.i editions for its cardiac catheterization and electrophysiology systems represents a well-timed portfolio enhancement addressing growing cardiovascular procedure volumes. With CVD affecting over 500 million people globally and both mortality and disability rates increasing, these workflow optimization tools target a genuine clinical need.
The technical improvements are substantive: Mac-Lab's integration of diastolic pressure ratio (dPR) algorithm expands coronary artery disease assessment capabilities, while CardioLab's Prucka 3 digital amplifier delivers superior signal quality for EP procedures. The collaboration with Volta Medical for real-time AI-based atrial fibrillation assessment is particularly noteworthy, as AF remains one of the most challenging arrhythmias to treat effectively.
ComboLab's integration of EP and hemodynamic recording creates workflow efficiencies that address staffing constraints in cardiac labs. These enhancements collectively represent evolutionary improvements rather than revolutionary technology, but they strengthen GE HealthCare's already strong position in the cardiovascular solutions space, validated by their recent Frost & Sullivan recognition.
The US-first launch strategy with subsequent global rollout is standard for medical technology and allows for real-world validation before wider deployment. Timing the announcement ahead of major cardiology conferences (EHRA and HRS) maximizes visibility among key physician adopters who influence purchasing decisions.
This product launch strengthens GE HealthCare's position in the high-margin cardiovascular intervention segment, which represents a significant growth opportunity as CVD rates continue rising globally. While the announcement lacks specific revenue projections, the cardiology solutions segment is strategically important for GEHC following its spin-off from General Electric.
The AI integration aligns with broader healthcare technology trends toward automation and clinical decision support, potentially creating differentiation in a competitive market. The company's decision to enhance existing platforms (Mac-Lab, CardioLab) leverages their installed base for potential upgrade revenue while requiring less customer retraining than entirely new systems.
The Frost & Sullivan recognition as 2025 Company of the Year validates GEHC's technology leadership position in electrophysiology, one of the faster-growing procedural areas in cardiology. EP procedures typically generate higher revenue per case than diagnostic catheterizations, making this a financially attractive focus area.
The collaboration with Volta Medical demonstrates GEHC's strategic approach to partnerships rather than developing all AI capabilities internally. This model can accelerate time-to-market while controlling R&D costs.
While reimbursement details aren't specified, hospitals increasingly prioritize technology investments that can improve procedural efficiency amid staffing constraints. GEHC's Command Center approach addresses this concern by optimizing workflow and visualization, potentially improving the value proposition for capital expenditure committees evaluating these systems.
- AltiX AI.i edition of Mac-Lab, CardioLab and ComboLab can enhance efficiency and precision care for multiple types of cardiac procedures
Cardiovascular disease (CVD) has nearly doubled over the past three decades, affecting more than 500 million people worldwide. During this period, both deaths and disabilities due to CVD have been on the rise globally.1 As cardiac cases continue to rise, there is an urgent need for tools that improve the efficiency of cardiac cath and EP procedures. Efficient diagnosis and therapy are key elements of addressing the growing demand for care.
“AltiX AI.i is built on more than two decades of experience, leadership and innovation in invasive cardiology to enhance cath labs and EP procedures and empower clinicians to deliver the best possible outcomes,” said Jyoti Gera, CEO, CardioVascular & Interventional Solutions, GE HealthCare. “By automating routine tasks and streamlining workflow, AltiX AI.i allows clinicians to focus on what truly matters – providing exceptional patient care.”
Mac-Lab for cardiac catheterization
The AltiX AI.i edition of Mac-Lab recording system combines functionality with workflow optimization. Clinicians can adopt this solution to elevate the cath lab user experience. The integration of the diastolic pressure ratio (dPR) algorithm allows users to easily perform this measurement, and builds on its ability to capture diastolic hyperemia-free ratio (DFR) measurements. These measurements are used to assess the severity of coronary artery disease. Mac-Lab provides optional Cath Lab Command Center access with a large display, advanced video and layouts, and customized documentation tools for a better user experience.
CardioLab for EP procedures
For EP procedures, the AltiX AI.i edition of CardioLab offers improved signal quality for visualization of physiological signals using the Prucka™ 3 digital amplifier. Prucka 3 is a solution that reduces environmental noise, maintains high signal fidelity and provides new signal-filtering capabilities for more advanced evaluations.2 The latest CardioLab edition showcases GE HealthCare’s collaboration with Volta Medical, Volta Interface, which utilizes PruckaStream to share real-time data to inform its Volta AF-Xplorer™ decision support system. The feature is designed to support clinicians with real-time assessments using artificial intelligence (AI) to automatically assess areas believed to initiate or maintain atrial fibrillation drivers. For an optimal visual experience, users can also harness the EP Command Center.
ComboLab for a comprehensive solution
ComboLab seamlessly integrates EP and hemodynamic recording into a single system, offering versatile functionality for both cath lab procedures and EP exams. ComboLab merges the best of Mac-Lab and CardioLab to give clinicians a comprehensive solution to manage various cardiac procedures in one location. Its familiar interface and workflow ease the learning curve, and its capability to document and export diagnostic data helps capture more information at the point of care.
"The introduction of AltiX AI.i reinforces our commitment to advancing cardiac care. These improved solutions are designed to enhance diagnostic and therapeutic capabilities, which are crucial for diagnosing and treating various heart conditions," said Arnaud Marie, General Manager, Interventional Solutions, GE HealthCare. "This launch is an important step in our ongoing mission to equip healthcare providers with interventional solutions that evolve alongside their needs."
In recognition of its innovation and leadership, GE HealthCare was recently honored by Frost & Sullivan as the 2024 Company of the Year in the Global Next-Generation EP Labs Industry. This prestigious award highlights GE HealthCare's commitment to growth and excellence in the field.
GE HealthCare will showcase the AltiX AI.i edition of Mac-Lab, CardioLab and ComboLab at the European Heart Rhythm Association (EHRA) 2025 annual congress taking place on March 30 - April 1 in
* AltiX AI.i is 510(k) cleared and CE mark pending.
About GE HealthCare Technologies Inc.
GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient’s journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a
GE HealthCare is proud to be among 2025 Fortune World’s Most Admired Companies™.
Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website https://www.gehealthcare.com for more information.
1 Roth, G, Mensah, G, Johnson, C. et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019: Update From the GBD 2019 Study. JACC. 2020 Dec, 76 (25) 2982–3021.
https://doi.org/10.1016/j.jacc.2020.11.010
2 GE HealthCare Data on File
View source version on businesswire.com: https://www.businesswire.com/news/home/20250316308035/en/
GE HealthCare Media Contact
Eric Tatro
GE HealthCare
+1 312 459 6140
Eric.Tatro@gehealthcare.com
Source: GE HealthCare Technologies Inc.
FAQ
What new features does GE HealthCare's AltiX AI.i edition offer for cardiac procedures?
When will GEHC's AltiX AI.i be available in global markets?
What are the three main products in GEHC's AltiX AI.i cardiac solution lineup?
What recognition did GEHC receive for its electrophysiology innovations?
